Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Diffuse Large Cell Lymphoma, Hodgkin Lymphoma, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Conditions
Brief summary
This is a multicentric, non-randomized, non-controlled open-label phase II trial to evaluate the safety and efficacy of treosulfan in a combination regimen with fludarabine as conditioning therapy prior to allogeneic stem cell transplantation (SCT) in patients with haematological malignancies. The aim is to demonstrate a clinical benefit compared with historical data on intravenous busulfan (BusulfexTM, BusilvexTM), the only drug so far registered in the indication conditioning before allogeneic stem cell transplantation.
Interventions
DRUGTreosulfan IV
Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
Sponsors
IRCCS San Raffaele
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with haematological malignancies, according to WHO classification, such as: * acute myeloid leukaemia -AML- in CR1 except low-risk cases defined by t(15;17), t(8;21), inv 16 or normal cytogenetics at diagnosis with FLT3-ITD negative and NPM-1 positive, with no high risk clinical criteria * any AML beyond CR1 * acute lymphoblast leukaemia -ALL- in CR1 only if at high risk defined by cytogenetics as t(9;22), t(4;11) or for persistence of minimal residual disease (MRD) * any ALL beyond CR1 * chronic myeloid leukaemia -CML- in chronic phase (CP) or accelerated phase (AP) intolerant/not responsive to TK-inhibitors * myeloproliferative disorders -MPD- * myelodysplastic syndrome -MDS- with intermediate or high risk International Prognostic Scoring System (IPSS) * diffuse large cell lymphoma -DLCL- with a chemosensitive relapse or beyond CR1 * lymphoblastic and Burkitt lymphoma with a chemosensitive relapse or beyond CR1 * mantle cell lymphoma -MCL- with a chemosensitive relapse or beyond CR1 * follicular lymphoma -FCL- with a chemosensitive relapse or beyond CR2 * Hodgkin lymphoma -HD- with a chemosensitive relapse or beyond CR1 * chronic lymphocytic leukaemia -CLL- at poor risk in CR1 or with a chemosensitive relapse * CLL relapsing after high dose chemotherapy * T-cell non Hodgkin lymphoma -T-NHL- in CR1 or beyond * multiple myeloma -MM- at high risk for cytogenetics or ISS stage 3 in CR1 following high dose chemotherapy * MM at any relapse/progression except refractory disease 2. Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor (MUD) * HLA-identity defined by the following markers: A, B, DRB1, DQB1 or a single or double Cord Blood unit (CB) with at least a 4 out of 6 HLA-matching by the following markers: A, B and DRB. A) identity between the 2 CB units and the recipient; B) Two identical CB units with one or two mismatches with the recipient; C) Two CB units with one mismatch between them and two mismatches with the recipient. We will prefer mismatches either for class I or for class II antigens; we will avoid mismatches concerning both classes I and II together. 3. Target graft size (unmanipulated, preferably not cryopreserved) * bone marrow: 2 to 10 x 106 CD34+ cells/kg BW recipient or \> 2 x 108 nucleated cells/kg BW recipient or * peripheral blood: 4 to 10 x 106 CD34+ cells/kg BW recipient 4. Age \> 18 and \< 70 years 5. Karnofsky Index \> 80 % 6. Adequate contraception in female patients of child-bearing potential 7. Written informed consent
Exclusion criteria
1. Secondary malignancies 2. Previous allogeneic transplantation 3. Hematopoietic cell transplantation-specific comorbidity index \> 4 (HCT-CI Sorror et al, Appendix M) 4. Known and manifested malignant involvement of the CNS 5. Active infectious disease 6. HIV- positivity or active hepatitis infection 7. Impaired liver function (Bilirubin \> upper normal limit; Transaminases \> 3.0 x upper normal limit) 8. Impaired renal function (Creatinine-clearance \< 60 ml/min; Serum Creatinine \> 1.5 x upper normal limit). 9. Pleural effusion or ascites \> 1.0 L 10. Pregnancy or lactation 11. Known hypersensitivity to treosulfan and/or fludarabine 12. Participation in another experimental drug trial within 4 weeks before day -6 13. Non-co-operative behaviour or non-compliance 14. Psychiatric diseases or conditions that might impair the ability to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy: Evaluation of engraftment | 28 days |
| Safety: Evaluation of the incidence of CTC grade 3 and 4 adverse events | between day -6 and day +28 |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy: Evaluation of relapse incidence (RI) | 1 year |
| Efficacy: Documentation of donor chimerism | on day +28, +56 and +100 |
| Safety: Evaluation of incidence of non-relapse mortality (NRM) | on day +28 and day +100 |
| Efficacy: Evaluation of disease free survival (DFS) | 1 year |
| Safety: Evaluation of cumulative incidence and severity of acute and chronic graft vs. host disease (GvHD) | 1 year |
| Safety: EBV reactivation | 1 year |
| Safety: cumulative incidence of NRM | 1 year |
| Efficacy: Evaluation of overall survival (OS) | 1 year |
Countries
Italy
Contacts
Primary ContactLuciano LC Callegaro, Monitor
Backup ContactStefania ST Trinca, Data Manager
Outcome results
None listed